Schering-Plough

April 2, 2008 -- "The full results of the study released today, showing that Vytorin had no effect on heart disease, put the lie to Merck and Schering-Plough’s $200 million advertising campaign urging Americans to take this drug.

While these corporations profited, Americans were left in the dark. The millions who take this drug, taxpayers who subsidize its use through the Medicaid and Medicare programs, and Merck and Schering-Plough’s investors deserve to know why it took so long for the results to be made public.

This new information underscores our concerns and advances our investigation, which we will pursue aggressively."

Source: New York Attorney General

Launches Investigation of Vytorin Makers

NEW YORK, NY -- January 26, 2008 -‑ New York Attorney General Andrew M. Cuomo announced the service of wide-ranging subpoenas on Merck & Co. (NYSE: MRK), Schering-Plough Corp. (NYSE: SGP), and Merck/Schering-Plough Pharmaceuticals seeking information about Vytorin, advertised as a highly-effective, cholesterol-lowering drug. In a two-pronged investigation, Cuomo is seeking to determine whether the companies deliberately concealed the negative results of a research trial about the efficacy of Vytorin.    » read more »